Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 16, 2023 (filed on Mar 17, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,973Price:$93.41
-
Mar 16, 2023 (filed on Mar 17, 2023)Insider Name:Fuchs Henry JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-36,000Price:$93.41
-
Mar 16, 2023 (filed on Mar 17, 2023)Insider Name:Davis George EricOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-19,957Price:$93.41
-
Mar 16, 2023 (filed on Mar 17, 2023)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-88,623Price:$93.41
-
Mar 16, 2023 (filed on Mar 17, 2023)Insider Name:Ajer Jeffrey RobertOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-20,510Price:$93.41
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,320Price:--
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,856Price:$87.74
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,900Price:--
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:21,970Price:--
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,708Price:$87.74
Filings by filing date
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,320Price:--
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,856Price:$87.74
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,900Price:--
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:21,970Price:--
-
Mar 16, 2023 (filed on Mar 17, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,973Price:$93.41
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,708Price:$87.74
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:9,630Price:--
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Fuchs Henry JOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy Common Stock)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:38,450Price:--
-
Mar 16, 2023 (filed on Mar 17, 2023)Insider Name:Fuchs Henry JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-36,000Price:$93.41
-
Mar 15, 2023 (filed on Mar 17, 2023)Insider Name:Fuchs Henry JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,799Price:$87.74
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 105 Digital Dr NOVATO CA 94949-8703 |
Tel: | N/A |
Website: | https://www.biomarin.com |
IR: | See website |
Key People | ||
Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer | Brian R. Mueller Chief Financial Officer, Executive Vice President - Finance | Henry J. Fuchs President - Worldwide Research and Development |
C. Greg Guyer Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer | G. Eric Davis Executive Vice President, General Counsel, Secretary | Jeff Robert Ajer Executive Vice President, Chief Commercial Officer |
Humaira Serajuddin Senior Vice President, Chief Marketing Officer | Erin Burkhart Group Vice President, Chief Accounting Officer |
Business Overview |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company's clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease. |
Financial Overview |
For the fiscal year ended 31 December 2022, Biomarin Pharmaceutical Inc revenues increased 14% to $2.1B. Net income before extraordinary items totaled $141.6M vs. loss of $68M. Revenues reflect Voxzogo segment increase from $5.9M to $169.1M, Naglazyme1 segment increase of 17% to $443.8M, Europe segment increase of 16% to $651M, Latin America segment increase of 40% to $266.8M. |
Employees: | 3,082 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $16,850M as of Dec 31, 2022 |
Annual revenue (TTM): | $2,096M as of Dec 31, 2022 |
EBITDA (TTM): | $143.53M as of Dec 31, 2022 |
Net annual income (TTM): | $141.56M as of Dec 31, 2022 |
Free cash flow (TTM): | $44.36M as of Dec 31, 2022 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 186,528,784 as of Feb 16, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |